LGD-4033 vs MK-2866 for performance
Short answer: For performance, users rate them about the same: 90% report improvement with LGD-4033 (226 reports) and 87% with MK-2866 (252 reports).
LGD-4033 has 1 meta-analyses and 1 randomized trials on PubMed; MK-2866 has 0 and 0.
Based on 630 reports about LGD-4033 and 789 about MK-2866. Not medical advice.
| LGD-4033 SARM | MK-2866 SARM | |
|---|---|---|
| Users say it helped | 48%helped353 reports · high confidence | 37%helped489 reports · high confidence |
| Verdict | Mixed | Mixed |
| Research | BResearch: Moderate | DResearch: None |
| Meta-analyses / RCTs | 1 / 1 | 0 / 0 |
| Mainly used for | ||
| Performance % reporting improvement | 90% (226) | 87% (252) |
| Hormones % reporting improvement | 4% (54) | 3% (100) |
| Weight loss % reporting improvement | 82% (45) | 88% (100) |
| Mood % reporting improvement | 23% (30) | 66% (64) |
| Recovery % reporting improvement | 88% (16) | 96% (78) |
| Common side effects | suppression, water retention, fatigue, stomach issues | suppression, fatigue, insomnia, headache |
| Typical dose reported | Not listed | Not listed |
LGD-4033Full LGD-4033 profile →
Latest review conclusion
SARMs have a positive effect on physical performance and body composition and are associated with moderate rates of mild to moderate adverse effects (AEs) and a low rate of severe AEs.
Clin Endocrinol (Oxf), 2025 ↗What a user said
“I've taken LDG-4033 and Ostarine from Ceretropic and noticed slight psychoactive effects from both, immediately (within 30 minutes after dosing).”
MK-2866Full MK-2866 profile →
What a user said
“I've taken LDG-4033 and Ostarine from Ceretropic and noticed slight psychoactive effects from both, immediately (within 30 minutes after dosing).”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate